OUTPUT Trademark

Trademark Overview


On Monday, October 3, 2022, a trademark application was filed for OUTPUT with the United States Patent and Trademark Office. The USPTO has given the OUTPUT trademark a serial number of 97617393. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, September 25, 2024. This trademark is owned by Jingu Health Inc.. The OUTPUT trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Therapeutics, pharmaceuticals, preventative therapies and nutraceuticals for preventing or treating diseases in a human subject, using targeted bioactives for the modulation of disturbed microbial ecosystems; Therapeutics, pharmaceuticals, preventative therapies and nutraceuticals for preventing or treating diseases in a human subject, via targeted modulation of a host microbial community; Therapeutics, pharmaceuticals, preventative therapies and nutraceuticals for the prevention and treatment of human diseases, namely, Autoimmune diseases and disorders, Bone and joint diseases and disorders, Cancer, Cardiovascular diseases and disorders, Gastro-intestinal diseases and disorders, Hematologic diseases and disorders, Infectious diseases and disorders, Kidney diseases and disorders, Lung diseases and disorders, Metabolic diseases and disorders, Muscle diseases and disorders, Nephrology diseases and disorders, Neurodegenerative diseases and disorders, Neurological diseases and disorders, O...

Computational biology platform for preventative therapies and nutraceuticals, namely non-downloadable software in the field of computational biology for use in the discovery, design, and optimization of therapeutics, pharmaceuticals, preventative therapies, and nutraceuticals; Computational biology platform for preventative therapies and nutraceuticals, namely, non-downloadable software in the field of computational biology for use in the research, development, and identification of disease mechanisms and therapeutic targets within the human microbiome; Computational biology platform for preventative therapies and nutraceuticals, namely, non-downloadable software in the field of computational biology for use in designing, forecasting results, running, and monitoring clinical trials, and selecting clinical trial participants, all related to clinical trials for therapeutics, pharmaceuticals, preventative therapies and nutraceuticals; Product development for others in the field of biotech...
output

General Information


Serial Number97617393
Word MarkOUTPUT
Filing DateMonday, October 3, 2022
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, September 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesTherapeutics, pharmaceuticals, preventative therapies and nutraceuticals for preventing or treating diseases in a human subject, using targeted bioactives for the modulation of disturbed microbial ecosystems; Therapeutics, pharmaceuticals, preventative therapies and nutraceuticals for preventing or treating diseases in a human subject, via targeted modulation of a host microbial community; Therapeutics, pharmaceuticals, preventative therapies and nutraceuticals for the prevention and treatment of human diseases, namely, Autoimmune diseases and disorders, Bone and joint diseases and disorders, Cancer, Cardiovascular diseases and disorders, Gastro-intestinal diseases and disorders, Hematologic diseases and disorders, Infectious diseases and disorders, Kidney diseases and disorders, Lung diseases and disorders, Metabolic diseases and disorders, Muscle diseases and disorders, Nephrology diseases and disorders, Neurodegenerative diseases and disorders, Neurological diseases and disorders, Ophthalmic diseases and disorders, Dermatological diseases and disorders, Inflammatory diseases and disorders, Immune disorders, Allergic disorders, Immuno-oncology and improving therapy outcome of Immuno-oncology therapies, Psychiatric diseases and disorders, Digestive diseases and disorders, Nutritional diseases and disorders, Malnutrition, Vaginal and penile diseases and disorders, Dysbioses, Fertility
Goods and ServicesComputational biology platform for preventative therapies and nutraceuticals, namely non-downloadable software in the field of computational biology for use in the discovery, design, and optimization of therapeutics, pharmaceuticals, preventative therapies, and nutraceuticals; Computational biology platform for preventative therapies and nutraceuticals, namely, non-downloadable software in the field of computational biology for use in the research, development, and identification of disease mechanisms and therapeutic targets within the human microbiome; Computational biology platform for preventative therapies and nutraceuticals, namely, non-downloadable software in the field of computational biology for use in designing, forecasting results, running, and monitoring clinical trials, and selecting clinical trial participants, all related to clinical trials for therapeutics, pharmaceuticals, preventative therapies and nutraceuticals; Product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents, and nutraceuticals; research and development of therapeutics related to preventative therapies, pharmaceuticals, and nutraceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 20, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 30, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOUTPUT BIOSCIENCES INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressNEW YORK, NY 10003

Party NameJingu Health Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events


Event DateEvent Description
Wednesday, May 3, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, October 20, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 18, 2023ASSIGNED TO EXAMINER
Thursday, July 27, 2023NON-FINAL ACTION WRITTEN
Thursday, July 27, 2023NON-FINAL ACTION E-MAILED
Thursday, July 27, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 24, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, October 24, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, January 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 4, 2024NON-FINAL ACTION WRITTEN
Monday, March 4, 2024NON-FINAL ACTION E-MAILED
Friday, May 31, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, March 4, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 31, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, September 4, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 4, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 4, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 25, 2024NON-FINAL ACTION E-MAILED
Wednesday, September 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, September 25, 2024NON-FINAL ACTION WRITTEN